1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Drug Substance Manufacturing
  6.  » Achieving Faster Timelines and Higher Titer in Antibody Expression When Combining GPEx® Cell Line Development Technology with the Beacon® Platform for Clonal Cell Line Selection

Achieving Faster Timelines and Higher Titer in Antibody Expression When Combining GPEx® Cell Line Development Technology with the Beacon® Platform for Clonal Cell Line Selection

Summary: Shortening timelines to generate more productive, stable and high-expressing cell lines is the goal of any cell line development program.  This case study explores the combination of Catalent’s unique GPEx® technology for stable gene product expression with Berkeley Lights, Inc.’s (BLI) Beacon® instrument for clonal selection.​

Click here to view the Case Study

Related Topics